Delphi Consensus Excessive Daytime Sleepiness in OSA

Sponsor
King's College London (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05055271
Collaborator
Jazz Pharmaceuticals (Industry)
10
1
20
0.5

Study Details

Study Description

Brief Summary

The objective of this study is to generate expert consensus statements on the differential diagnosis, definition, and management of EDS in patients with OSA who are adequately treated with primary therapy.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    A study will be performed using a modified Delphi process with an international expert panel to generate recommendation statements related to the differential diagnosis and management of patients with residual EDS in OSA (and relevant sub-topics) and to determine the level of agreement for each statement from the panel as a whole. The following topics will be covered:

    1. EDS: definition, evaluation/assessment, and tools

    2. Definitions of residual EDS in patients with OSA treated with primary OSA therapy

    3. Practical recommendations

    4. Management Consensus is achieved through iterative rounds of survey and revision to the statements until a pre-determined level of agreement is met (80% agreement).

    Part 1: planning and evidence review

    • Series of planning sessions with co-chairs and faculty leads

    • Literature is reviewed/summarized

    • Initial statements will be developed based on evidence Recommendation statements on EDS in OSA will be formulated and rated according to level of agreement on a 5-point Likert scale.

    Part 2: Survey to achieve consensus

    • Survey, based on the initial statements developed by faculty leads, will be developed to allow for vetting by full faculty group

    • At least 3 rounds of review (2 remote and 1 live [virtual]) will be held to achieve consensus on each topic of interest and finalize consensus statements

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    10 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Differential Diagnosis and Management of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea: A Modified Delphi Consensus Panel Report
    Actual Study Start Date :
    Apr 1, 2021
    Anticipated Primary Completion Date :
    Jun 1, 2022
    Anticipated Study Completion Date :
    Dec 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Delphi panel

    The Delphi panel will include 10 international experts in sleep and respiratory medicine. Two panelists will serve as co-chairs and eight panelists will serve as section leads for the major topic areas throughout the process. A series of planning sessions will be conducted with the co-chairs and section leads prior to implementation of the survey.

    Outcome Measures

    Primary Outcome Measures

    1. Consensus [6 months]

      The level of agreement for all statements achieving consensus from the expert panel; consensus is predefined as ≥ 80% of the panel rating a given statement A+ or A.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Members of the panel include experts in sleep and respiratory medicine in North American and Europe.
    Exclusion Criteria:
    • Panelists who were not able to commit to all rounds of the modified Delphi process will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 King's College London London United Kingdom SE1 7EH

    Sponsors and Collaborators

    • King's College London
    • Jazz Pharmaceuticals

    Investigators

    • Study Chair: Joerg Steier, PhD, King's College London (KCL), UK
    • Study Chair: Atul Malhotra, MD, University of California San Diego (UCSD), USA

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Professor Joerg Steier, Professor of Respiratory and Sleep Medicine, King's College London
    ClinicalTrials.gov Identifier:
    NCT05055271
    Other Study ID Numbers:
    • 2021 EDS in OSA Delphi V1.0
    First Posted:
    Sep 24, 2021
    Last Update Posted:
    Mar 31, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Professor Joerg Steier, Professor of Respiratory and Sleep Medicine, King's College London
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 31, 2022